Pleuritis Induced by Brigatinib During the Treatment of Non‐Small Cell Lung Cancer Authors: Shohei Yano, Moon Hee Hwang, Tomoko Harima, Shota Takahashi, Takumi Yamada, Nao Yoshida, Yuki Yoshida, Atsushi Hirai Published: 2026 ABSTRACT ABSTRACTThis report describes the first documented case of brigatinib‐induced pleuritis in a patient with ALK‐positive non‐small cell lung cancer. A 77‐year‐old woman developed dyspnoea, fever, elevated inflammatory markers, and bilateral pleural effusion shortly after starting brigatinib as third‐line therapy. Pleural fluid analysis showed lymphocyte‐predominant exudative effusion without evidence of malignancy or infection, suggesting drug‐induced pleuritis. Discontinuation of brigatinib led to rapid clinical and radiographic improvement. Although disease progression later occurred, pleuritis did not recur. Re‐administration of brigatinib at a reduced dose of 30 mg/day achieved tumour shrinkage without pleuritis recurrence, and subsequent dose escalation to 60 mg/day was also tolerated. This case highlights that clinicians should consider drug‐induced pleuritis when pleural effusion develops during brigatinib therapy, particularly when it is inconsistent with the disease progression. Dose reduction to as low as 30 mg/day may be a safe and effective therapeutic option for selected patients.Keywords: brigatinib, non‐small cell lung cancer, pleuritis Introduction Brigatinib, an anaplastic lymphoma kinase (ALK) inhibitor, demonstrated efficacy in the ALTA‐1L trial [1] and is a first‐line treatment for ALK‐positive non‐small cell lung cancer (NSCLC). Although some drugs such as methotrexate, amiodarone, and nitrofurantoin can trigger pleuritis, reports of brigatinib‐induced pleuritis are scarce [2]. Herein, we report a case of brigatinib‐induced pleuritis that was successfully managed with drug discontinuation and dose reduction. Case Report A 77‐year‐old woman was diagnosed with stage IVA lung adenocarcinoma (cT4N3M1a) 3 years prior. ALK fusion gene was positive and PD‐L1 expression was 90%. The patient received first‐line alectinib, followed by second‐line carboplatin, paclitaxel, bevacizumab, and atezolizumab. Twenty‐eight days before visiting our institution, the patient had commenced third‐line brigatinib treatment (90 mg/day). The dose was increased to 180 mg for 3 days but reduced to 90 mg owing to elevated creatinine kinase levels. The patient was admitted to our outpatient clinic with dyspnoea. The patient's temperature was 37.9°C, oxygen saturation was 89% (room air), and C‐reactive protein (CRP) level was elevated to 13.76 mg/dL. Albumin level was decreased to 2.8 g/dL. Other serological tests, including autoantibodies, did not suggest connective tissue disease. Chest radiography and CT revealed bilateral pleural effusion (Figures 1A,B and 2A,B). The primary lesion showed a therapeutic response to brigatinib. Echocardiography revealed no evidence of heart failure. Pleural fluid analysis indicated a lymphocyte‐predominant exudative effusion, and no eosinophils were detected. Cytological and bacterial culture results were negative. Adenosine deaminase levels were within the normal range. Chest X‐ray images before initiation of brigatinib (A), the day of admission (B), and Hospital Day 11 (C). Computed tomography (CT) images before initiation of brigatinib (A), the day of admission (B), one month later, discontinuation of brigatinib (C), before and two months after resumption of brigatinib (D and E). Brigatinib was discontinued on the day of admission. Two days later, the patient's fever resolved. On Hospital Day 11, the pleural effusion volume decreased (Figure 1C), and the CRP level declined to 0.92 mg/dL. Based on the clinical course, brigatinib‐induced pleuritis was suspected. One month later, the primary lesion started to grow, without increased pleural effusion (Figure 2C). Eight months later, the patient was re‐administered brigatinib. The patient was concerned about the relapse of adverse events, so we started at the lowest prescribable dose of 30 mg/day and monitored adverse effects. Eventually, this led to a therapeutic response without pleuritis recurrence (Figure 2D,E); therefore, the same dose was maintained. Nine months after drug resumption, the disease progressed and the brigatinib dose was increased to 60 mg/day. This was continued for an additional 2 months without pleuritis recurrence but was ineffective. Moreover, subsequent lorlatinib treatment was unsuccessful, and the patient died 1 month later. Discussion To the best of our knowledge, this is the first reported case of brigatinib‐induced pleuritis. Although pleural effusion has been reported as an adverse event in phase 1 and 2 trials of brigatinib [3], its causal relationship with the drug has not been clearly established. In this case, Infectious pleuritis was considered unlikely because the pleural fluid culture yielded no bacteria. Additionally, malignant pleuritis was improbable because the lung cancer was controlled, pleural fluid cytology showed negative results and pleural effusion decreased without anticancer therapy. Echocardiography did not indicate cardiac disfunction. Low albuminemia frequently show bilateral effusion; however, the effusion is usually transudative and occurs without fever. The improvement observed following the discontinuation of brigatinib suggested drug‐induced pleuritis. In some reported cases, brigatinib was successfully rechallenged after drug‐induced pneumonitis [4]. Therefore, successful rechallenge does not necessarily exclude a drug‐related mechanism. In addition, a comparatively low dose of brigatinib (30 mg) was effective. In the ALTA‐1L trial, brigatinib was initiated at a dose of 180 mg, with a lead‐in period of 90 mg [1]. If patients are unable to tolerate a 60‐mg dose due to adverse reactions, permanent discontinuation is typically recommended [5]. In the present case, to avoid pleuritis recurrence, a 30‐mg dose was administered, resulting in a clinical response. Although its efficacy has not been firmly established, 30 mg brigatinib may be a safe and efficacious option for selected patients. However, mechanisms underlying pleuritis remain unknown. The aetiology of drug‐induced pleural disease is generally considered to involve hypersensitivity or allergic reaction, direct toxic effect, increased oxygen free radical production, suppression of the antioxidant defence, and chemically induced inflammation [6]. Pleuritis did not occur at a reduced dose of brigatinib in our case; therefore, the occurrence of pleuritis could be dose‐dependent rather than related with immune‐mediated reaction. Among ALK tyrosine kinase inhibitors (TKIs), alectinib‐induced pleuritis resolves after switching to brigatinib [7]. In the present case, pleuritis did not occur during treatment with alectinib or lorlatinib. These observations suggest that pleuritis induced by ALK TKIs may not arise from a common pathophysiology shared among these agents but rather from drug‐specific pathomechanisms. Therefore, switching to another ALK TKI may be a viable option if pleuritis cannot be controlled with a particular ALK TKI. This case highlights the potential of brigatinib to induce pleuritis and suggests that this adverse event may be managed through drug discontinuation or dose reduction. When progressive pleural effusion is observed during brigatinib treatment, drug‐induced pleuritis should be considered, especially if it is inconsistent with disease progression. Pleuritis can be controlled by adjusting the treatment regimens. A reduction to 30 mg may be a safe and efficient option in some cases. Author Contributions Shohei Yano contributed to patient history documentation and drafting the initial manuscript. Moon Hee Hwang and Shota Takahashi contributed to manuscript editing. All authors reviewed and approved the final version of the manuscript. Consent The authors declare that written informed consent was obtained for the publication of this manuscript and accompanying images using the consent form provided by the Journal. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgements We thank the patient and all medical staffs. We thank Editage (www.editatge.com) for English language editing. Yano S., Hwang M. H., Harima T., et al., “Pleuritis Induced by Brigatinib During the Treatment of Non‐Small Cell Lung Cancer,” Respirology Case Reports 14, no. 5 (2026): e70598, 10.1002/rcr2.70598. Associate Editor: Ken Tajima Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study.